3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
6
Other solid neoplasm
4
Sarcoma
3
Tumor-Agnostic
2
Head & Neck
2
Genitourinary
2
Endocrine
2
CNS
2
NET
1
Lymphoid
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Thyroid Cancer, Papillary
1
Sarcoma
1
Salivary Gland Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Melanoma
1
Lymphoma, Large-Cell, Anaplastic
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Everolimus
18
lutetium Lu 177 dotatate
9
lanreotide
8
surufatinib
7
Octreotide
7
pasireotide
5
amino-acid, glucose, and electrolyte solution
5
Sunitinib
5
Temozolomide
4
Data Collection
4
pembrolizumab
3
177Lu-octreotide, DOTA(0)-Tyr(3)-
3
tislelizumab
2
fosbretabulin
2
arginyllysine
2
anlotinib
2
Paclitaxel
2
PM 01183
2
Lutetium-177
2
Lutetium
2
Irinotecan
2
Injections
2
Carboplatin
2
64Cu-SARTATE
2
3-Iodobenzylguanidine
2
toripalimab
1
telotristat ethyl
1
taxane
1
repotrectinib
1
pralsetinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
entrectinib
×
NET
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA